On October 19, 2021 /PRNewswire/ — PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, reported that the patent for PMC-309, one of the Company’s first immuno-oncology assets, has been granted by IP Australia, the Australian government agency that administers intellectual property rights (Press release, PharmAbcine, OCT 19, 2021, View Source;bmode=view&idx=8574626&t=board [SID1234649186]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Australian grant represents PMC-309’s third global patent approval since it received grants from Russia in June 2021 and South Korea in July 2021. The Company also plans to get more patents approved in other countries, including the U.S, Canada, China, Japan, European nations, and etc.

PMC-309 is a first-in-class antibody that antagonizes VISTA (V-domain Ig Suppressor of T cell Activation) and is in development to treat various tumor types. VISTA plays a pivotal role in maintaining the immunosuppressive environment around the tumor cells and is expressed primarily on immunosuppressive cells, such as MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells). Blocking VISTA pathways on immunosuppressive cells promotes T cells’ immune responses and leads to better anti-tumor effects.

According to the nonclinical data of PMC-309 presented at AACR (Free AACR Whitepaper) (American Association for Cancer Research) 2021, PMC-309 showed promising anti-tumor effects comparable to an existing anti-PD-1 drug. However, when used in combo with an anti-PD-1 drug, PMC-309 demonstrated significantly improved tumor growth inhibitions than either mono therapies.

In April 2021, PharmAbcine initiated IND-enabling studies of PMC-309. The studies are required to establish the safety profile in animals before entering the human trial. The Company expects to enter a Phase I global trial in 2022.

"This patent grant is one of the key milestones that underlines our approach to help patients with unmet medical needs with a novel first-in-class antibody candidate and builds stronger intellectual property position in the immuno-oncology field," said Dr. Jin-San Yoo, CEO of PharmAbcine. "Our team believes that PMC-309, with its unique mode of action that does not overlap with the existing drugs, will be a new treatment option in both mono and combo therapies for patients who do not respond well to the current immunotherapies."

On October 19, 2021 Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, reported that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19th (Press release, Cannabics Pharmaceuticals, OCT 19, 2021, View Source [SID1234592177]). Mr. Barad’s talk will focus on the pharmaceutical development of synthetic cannabinoid-based drug candidates for colorectal cancer and other cancers designated for FDA regulatory review.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eyal Barad, Cannabics Pharmaceuticals Co-Founder and CEO said: "We are proud to have been selected to present at Edison’s Open Forum Conference and share our perspective on synthetic cannabinoid drug development and on the challenges, opportunities and trends we see in the industry."

To access the Forum and the presentation please register at the following link:

View Source

On October 19, 2021 Aadi Bioscience, Inc. ("Aadi"), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at H.C. Wainwright’s 2nd Annual Precision Oncology Conference, which will be held virtually (Press release, Aadi Bioscience, OCT 19, 2021, View Source [SID1234592016]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Information:

Date: Wednesday, October 20, 2021

Time: 1 pm ET

To Listen to the Presentation:

The live webcast can be accessed here: View Source A replay will also be available at this link for 90 days and posted on Aadi’s website within the Investors & News/Events & Presentations section.

On October 19, 2021 Scapa Healthcare, an SWM International (NYSE: SWM) business and the trusted strategic partner for the world’s leading companies in advanced wound care, consumer wellness, and medical device and fixation, and Synedgen Inc., a biotechnology company using glycochemistry to develop drugs that enhance and mimic the innate immune system, reported that they have signed an exclusive worldwide licensing agreement for two novel innovative wound care treatments developed using Synedgen’s proprietary glycochemistry technology platform (Press release, Synedgen, OCT 19, 2021, View Source;utm_medium=rss&utm_campaign=swm-internationals-scapa-healthcare-business-signs-exclusive-technology-licensing-agreement-for-novel-wound-care-technology-with-synedgen-inc [SID1234591667]). The agreement also gives Scapa Healthcare the right to use Synedgen’s glycopolymer technology in conjunction with other wound care technologies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Scapa Healthcare has exclusive rights over Synedgen’s glycopolymer technology in the field of dermal wounds and surgical care applications both over the counter and in the professional setting.

The advanced glycopolymer-based wound cleanser and wound hydrogel formulae are proven to control infection and promote wound healing by limiting bacterial infection, disrupting mature biofilm, and reducing inflammation and scarring of acute and chronic wounds and surgical incisions. Developed with support from the Defense Health Agency (DHA) and the Defense Advanced Research Projects Agency (DARPA), these wound care products are FDA 510(k) cleared and offer substantial advances over existing wound cleansers and wound hydrogels products in the market.

In addition to the two market-ready products, this technology offers a wide range of possibilities for customized wound management solutions in combination with other advanced wound care technologies including hydrocolloids, hydrogels, collagen and medical foam materials.

"We are delighted to be entering into this agreement with Synedgen, a company that shares our commitment to deliver innovative medical solutions that truly enhance people’s lives" said John Petreanu, president of the Scapa Healthcare business. "This novel glycopolymer technology strengthens our portfolio of advanced wound care products and enables us to bring cutting-edge wound management solutions to our customers in a variety of formats leveraging our skin contact adhesive and topical technologies."

"This agreement with Scapa Healthcare will expand Synedgen’s effective approach to treating challenging wounds for patients worldwide," said Shenda Baker, PhD, President and CEO of Synedgen. "With a rich Defense heritage, we have been able to create a new class of wound care products for warfighter and civilian use. We are honored to partner with such a well-known, world industry leader that adds to the level of consumer trust and experience to expand the application and distribution of this technology."

With development and manufacturing facilities throughout North America and Europe, Scapa Healthcare offers single-source, dual supply to its partners. Scapa Healthcare’s facilities are ISO-certified and FDA-registered with cleanrooms and environmentally controlled rooms for full-scale production of finished goods. In April 2021, Schweitzer-Mauduit International, Inc., known as SWM International, acquired Scapa Group PLC, including the Scapa Healthcare business.

On October 19, 2021 Kureha Corporation reported that it has resolved at the meeting of the Board of Directors held to pay the following dividends to shareholders held in record as of September 30, 2021 (Press release, Kureha Corporation, OCT 19, 2021, View Source [SID1234591572]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Details of dividend payment

2. Reasons
Kureha’s basic policy regarding dividend distribution is to pay a steady dividend to shareholders over a long period of time, while strengthening the company’s financial structure to sustain long-term growth and future business development. From this standpoint, Kureha has determined to pay 85 yen per share for the FY2021 interim dividend, which is unchanged from its most recent forecast.